Table 2.

Comparison of RiVax and RVEc Phase I and NHP Studies

	Humans		R. macaques
	RVEca	RiVaxa	RiVaxa
Trial IDb	NCT01317667 NCT01846104	NCT00812071
Group size (n=)	10	5	12
Groups (µg)	20, 50, 100	1,10,100	100
Vaccination-days	0, 28, 56	0, 42, 180	0, 30, 60
AEc	2/30	1/14 (Grade III)	n.a.
Peak endpoint-day	84	210	75
Peak titers	4500–4800d	25–260 µg/ml	1534 µg/ml
Peak TNA-day	70	n.r.	110
Peak TNA-titer	73–78e	20–24f	1280f
Ab half life-day	100	180	n.r.
Reference	[65]	[66]	[47]

^aAdsorbed to Alhydrogel;

^bclinicaltrials.gov identifier number(s);

^cAdverse events (AE). In the RiVax trial, s all volunteers experienced Grade I toxicities, one individual suffered Grade II headache and Grade III nausea. In the RVEc trial, one individual suffered shoulder injury related to vaccine administration, while another suffered rhabdomyolysis;

^drefers to GMT of reciprocal endpoint determined by ELISA using ricin-coated plates;

^ereciprocal toxin-neutralizing endpoint titers (IC₅₀) established in Daudi cells;

^freciprocal dilution of serum that conferred positive toxin-neutralizing activity in EL4 cells;n.a., not applicable, n.r., not reported.